Inmune Bio Stock Investor Sentiment
INMB Stock | USD 8.17 0.22 2.77% |
About 63% of all INmune Bio's investors are looking to take a long position. The analysis of the overall investor sentiment regarding INmune Bio suggests that some traders are interested. The current market sentiment, together with INmune Bio's historical and current headlines, can help investors time the market. In addition, many technical investors use INmune Bio stock news signals to limit their universe of possible portfolio assets.
INmune |
INmune Bio Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards INmune Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
INmune Bio Maximum Pain Price Across April 17th 2025 Option Contracts
INmune Bio's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of INmune Bio close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of INmune Bio's options.
Far too much social signal, news, headlines, and media speculation about INmune Bio that are available to investors today. That information is available publicly through INmune media outlets and privately through word of mouth or via INmune internal channels. However, regardless of the origin, that massive amount of INmune data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of INmune Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of INmune Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to INmune Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive INmune Bio alpha.
INmune Bio Performance against Dow Jones
Price Growth (%) |
Timeline |
1 | Acquisition by Allen Marcia of 32500 shares of INmune Bio at 5.05 subject to Rule 16b-3 | 12/20/2024 |
2 | Acquisition by Lowdell Mark William of 14423 shares of INmune Bio at 8.32 subject to Rule 16b-3 | 12/31/2024 |
3 | Acquisition by Moss David J of 160000 shares of INmune Bio at 9.92 subject to Rule 16b-3 | 01/24/2025 |
4 | INmune Bio Rating Increased to Strong-Buy at RODMANRENSHAW - MarketBeat | 01/29/2025 |
5 | Acquisition by Xencor Inc of 192533 shares of INmune Bio at 17.14 subject to Rule 16b-3 | 01/30/2025 |
6 | Acquisition by Schroeder Timothy J of 12500 shares of INmune Bio at 9.92 subject to Rule 16b-3 | 01/31/2025 |
7 | Why INmune Bio Inc Is Skyrocketing So Far In 2025 - Yahoo Finance | 02/03/2025 |
8 | Why INmune Bio Inc Is Skyrocketing So Far In 2025 | 02/04/2025 |
9 | INmune Bio Announces Plan to Submit FDA Biologics License Application Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa | 02/10/2025 |
10 | INmune Bio Opens Phase II in High Dose Cohort of INKmune Trial in Prostate Cancer | 02/12/2025 |
11 | Acquisition by Baracchini Edgardo Jr of 35000 shares of INmune Bio subject to Rule 16b-3 | 03/05/2025 |
12 | Acquisition by Lowdell Mark William of 140000 shares of INmune Bio at 5.05 subject to Rule 16b-3 | 03/07/2025 |
Complementary Tools for INmune Stock analysis
When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Bonds Directory Find actively traded corporate debentures issued by US companies |